ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 954,48
1,85%
DAX
18 518,03
-0,44%
Brent Oil
83,335
-1,19%
Bitcoin
64 690,68
-0,25%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
03/01/202322h30Business WireTeva to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/202210h00GlobeNewswire Inc.Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
13/12/202219h24Dow Jones NewsVanda Pharmaceuticals Shares Tumble After Loss in Hetlioz Patent SuitNYSE:TEVATeva Pharmaceutical Industries Ltd
23/11/202208h44Dow Jones NewsTeva, Allergan Finalize Terms of Nationwide Opioid Settlement -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
22/11/202214h30Business WireTeva Finalizes Nationwide Opioid Settlement TermsNYSE:TEVATeva Pharmaceutical Industries Ltd
21/11/202213h02Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
21/11/202213h00Business WireTeva Announces Appointment of Richard Francis as President and CEONYSE:TEVATeva Pharmaceutical Industries Ltd
14/11/202214h01Business WireTeva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health PlatformNYSE:TEVATeva Pharmaceutical Industries Ltd
14/11/202214h00Business WireTeva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health PlatformNYSE:TEVATeva Pharmaceutical Industries Ltd
10/11/202214h54TipRanksEli Lilly (NYSE:LLY) Loses Migraine Drug Patent Trial to TevaNYSE:TEVATeva Pharmaceutical Industries Ltd
07/11/202222h30Business WireTeva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
07/11/202217h40TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and Teva Pharmaceutical (TEVA)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/11/202221h16Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/11/202212h00Business WireTeva Reports Third Quarter 2022 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
25/10/202216h00Business WireClinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFCNYSE:TEVATeva Pharmaceutical Industries Ltd
18/10/202214h00Business WireTeva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s DiseaseNYSE:TEVATeva Pharmaceutical Industries Ltd
10/10/202212h39Dow Jones NewsTeva Might Have Broken Competition Rules, EU Watchdog Says -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
10/10/202210h34Dow Jones NewsEU Watchdog Says Teva Might Have Misused Patent System to Hinder CompetitionNYSE:TEVATeva Pharmaceutical Industries Ltd
07/10/202222h44TipRanksTeva tells Bloomberg it sees Adderall supply issues for next 2-3 monthsNYSE:TEVATeva Pharmaceutical Industries Ltd
07/10/202217h01Dow Jones NewsCorrection to Teva ArticleNYSE:TEVATeva Pharmaceutical Industries Ltd
07/10/202215h18Dow Jones NewsTeva Pharmaceutical Reaches Fourth U.S. Settlement Over Price-Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
07/10/202214h30Business WireTeva Reaches Agreement With Arkansas to Settle the State’s Price Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
06/10/202222h00Business WireTeva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022NYSE:TEVATeva Pharmaceutical Industries Ltd
06/10/202214h34Business WireTeva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related OutcomesNYSE:TEVATeva Pharmaceutical Industries Ltd
30/09/202215h00Dow Jones NewsTeva Pharmaceutical Reaches Third State Settlement Over Price-Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/09/202214h00Business WireTeva Reaches Agreement With Georgia to Settle the State’s Price Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
26/09/202214h00Business WireTeva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD ChoreaNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/202221h58Business WireDes études démontrent l'efficacité d'AJOVY®▼ (frémanézumab) dans le traitement de la migraine chez des patients présentant une dépression comorbideNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/202220h29Business WireStudien zeigen Wirksamkeit von AJOVY®▼ (Fremanezumab) bei der Behandlung von Migräne bei Patientinnen und Patienten mit komorbider DepressionNYSE:TEVATeva Pharmaceutical Industries Ltd
08/09/202207h45Business WireStudies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid DepressionNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

BOV
FSPM11
F3 Fundshares Portfolio ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés